<DOC>
	<DOCNO>NCT02378532</DOCNO>
	<brief_summary>Patients glioblastoma ( GBM ) poor prognosis median survival 14.6 month maximal treatment resection chemoradiation . Since pivotal trial evaluate effect temozolomide ( TMZ ) , overall survival increase . Treatment GBM xenograft vivo chloroquine ( CQ ) , antimalarial agent , show reduce hypoxic fraction sensitize tumor radiation . Epidermal growth factor receptor ( EGFR ) amplification mutation regularly observe GBM think major contributor radioresistance . The common EGFR mutation GBM ( EGFRvIII ) present 50-60 % patient whose tumor show amplification EGFR . EGFR provide cell survival advantage autophagy expose stress hypoxia nutrient starvation . This effect even pronounce EGFRvIII overexpressing tumor . Previously , potential effect CQ demonstrate small randomized control trial GBM treat radiotherapy carmustine , show trend towards increase overall survival . However , intracellular effect chloroquine dose-dependent maximum tolerate dose CQ combination concurrent radiotherapy daily temozolomide need establish .</brief_summary>
	<brief_title>The Addition Chloroquine Chemoradiation Glioblastoma</brief_title>
	<detailed_description>This trial design open label , single center combination phase I trial . The primary objective determine maximum tolerate dose ( MTD ) chloroquine ( CQ ) combination concurrent radiotherapy daily temozolomide patient newly diagnose GBM . Eligible patient receive radiotherapy chemotherapy accord standard protocol newly diagnose GBM . This consist 33 daily fraction 1.8 Gy tumor surround margin combination TMZ 75 mg/m² per os daily ( po qd ) six adjuvant cycle TMZ 150 - 200 mg/m² po qd . Treatment combine daily intake escalate dos chloroquine . Chloroquine start week start radiotherapy end last day radiotherapy . The rate subject entry escalation next dose level depend upon assessment safety profile patient enter previous dose level . Toxicity evaluate accord NCI common Terminology Criteria Adverse Events ( CTCAE ) , Version 4.0 . The 3 + 3 cohort method use . A minimum three patient enter dose level . All three follow concomitant radiotherapy 4 week observation period escalation next dose level . The start dose 200mg chloroquine daily . Before open next high dose level toxic effect precede dose level review expansion escalation undertaken appropriate</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>Histologically confirm grade IV supratentorial astrocytoma ( glioblastoma multiforme ) Tumor tissue available histopathological analysis ( MGMT , EGFRvIII ) Diagnosis must make biopsy resection ≤ 3 month prior study entry 18 year old Karnofsky performance status ≥ 70 Absolute neutrophil count least 1.5 x 109/L platelet least 100 x109/L Adequate renal function Adequate hepatic function absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule . Females must negative result pregnancy test perform No breast feeding . If male , subject must surgically sterile practice method contraception Prior radiotherapy Prior chemotherapy Recent ( &lt; 3 month ) severe cardiac disease ( NYHA class &gt; 1 ) ( congestive heart failure , infarction ) History cardiac arrythmia ( multifocal premature ventricular contraction , uncontrolled atrial fibrillation , bigeminy , trigeminy , ventricular tachycardia ) symptomatic require treatment ( CTC AE 4.0 ) , asymptomatic sustain ventricular tachycardia . Asymptomatic atrial fibrillation control medication allow . Cardiac conduction disturbance medication potentially cause Treatment investigational drug 4 week prior study If subject clinically significant uncontrolled major medical condition ( ) include limited : uncontrolled nausea/vomiting/diarrhea : active uncontrolled infection , include HIV hepatitis ( HBV , HCV ) psychiatric illness/social situation would limit compliance study requirement medical condition , opinion study investigator , place subject unacceptably high risk toxicity . The subject another active malignancy within past 3 year except cancer situ principal Investigator considers cure . Chronic systemic immune therapy ( exception corticosteroid ) Concurrent cytochrome P450 enzymeinducing anticonvulsant drug ( e.g. , phenytoin , carbamazepine , phenobarbital , primidone , oxcarbazepine ) Known glucose6phosphate dehydrogenase deficiency Psoriasis porphyria Known hypersensitivity 4aminoquinoline compound Retinal visual field change unrelated tumor location prior 4aminoquinoline compound use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Chloroquine</keyword>
	<keyword>Autophagy</keyword>
	<keyword>EGFRvIII</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Temozolomide</keyword>
</DOC>